Overview

Ivermectin Nasal Spray for COVID19 Patients

Status:
Not yet recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The global escalation of COVID19 pandemic has put the health care system under pressure with urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight this pandemic.

Phase:

Phase 2

Details

Lead Sponsor:

Tanta University

Treatments:

Ivermectin